Study S000965

Effect of AC2993 (Synthetic Exendin-4) Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT00082381
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: COMPLETED
Enrollment: 551
Start: 2003-06
Primary completion: 2008-07
Lead sponsor: AstraZeneca
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:Exenatide (AC2993); DRUG:Insulin glargine
Results posted: TRUE

Registered primary outcomes

Change in Glycosylated Hemoglobin (HbA1c) [Baseline, week 26]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0018919	Exenatide twice daily: analysis of effectiveness and safety data stratified by age, sex, race, duration of diabetes, and body mass index. Pencek R, Postgraduate medicine	2012	Randomized trial	PMID 22913891 DOI	cites ClinicalTrials.gov:NCT00082381; registry reference DERIVED:22913891
R0026474	Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment. Fineman MS, Diabetes, obesity & metabolism	2012	Other	PMID 22236356 DOI	cites ClinicalTrials.gov:NCT00082381; registry reference DERIVED:22236356
R0027640	Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Heine RJ, Annals of internal medicine	2005	Randomized trial	PMID 16230722 DOI	cites ClinicalTrials.gov:NCT00082381; registry reference RESULT:16230722